Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H33ClN2O5S |
Molecular Weight | 424.983 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O)[C@H](NC(=O)[C@@H]2C[C@@H](CCC)CN2C)[C@H](C)Cl
InChI
InChIKey=KDLRVYVGXIQJDK-AWPVFWJPSA-N
InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1
Molecular Formula | C18H33ClN2O5S |
Molecular Weight | 424.983 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050441s072,050639s033lbl.pdfCurator's Comment: description was created based on several sources, including:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050537s035,050600s013,050615s012lbl.pdf | http://www.rxlist.com/clindamycin-phosphate-topical-solution-drug.htm
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050441s072,050639s033lbl.pdf
Curator's Comment: description was created based on several sources, including:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050537s035,050600s013,050615s012lbl.pdf | http://www.rxlist.com/clindamycin-phosphate-topical-solution-drug.htm
Clindamycin phosphate is the prodrug of clindamycin with no antimicrobial activity in vitro but can be rapidly converted in vivo to the parent drug, clindamycin, by phosphatase ester hydrolysis. It is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes; Skin and skin structure infections; Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes; Intra-abdominal infections; Septicemia; Bone and joint infections. Orally and parenterally administered clindamycin has been associated with severe colitis, which may end fatally. Abdominal pain, gastrointestinal disturbances, gram-negative folliculitis, eye pain and contact dermatitis have also been reported in association with the use of topical formulations of clindamycin. Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC105985/pdf/ac003014.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/9797245
Curator's Comment: Clindamycin phosphate is the prodrug of clindamycin
with no antimicrobial activity in vitro but can be rapidly converted in vivo to the parent drug, clindamycin, by phosphatase ester hydrolysis.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12860123 |
|||
Target ID: CHEMBL2363135 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.4928E9 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.4928E9 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.4928E9 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.4928E9 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.4928E9 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.4928E9 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.4928E9 |
|||
Curative | CLEOCIN T Approved UseClindamycin Phosphate is indicated in the treatment of acne vulgaris. Launch Date3.31862409E11 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseLower respiratory tract infections including pneumonia, empyema, and lung abscess
caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis),
and Staphylococcus aureus. Launch Date8.6745596E10 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseSkin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus
aureus, and anaerobes. Launch Date8.6745596E10 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseGynecological infections including endometritis, nongonococcal tubo-ovarian abscess,
pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Launch Date8.6745596E10 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseIntra-abdominal infections including peritonitis and intra-abdominal abscess caused by
susceptible anaerobic organisms. Launch Date8.6745596E10 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseSepticemia caused by Staphylococcus aureus, streptococci (except Enterococcus
faecalis), and susceptible anaerobes. Launch Date8.6745596E10 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseBone and joint infections including acute hematogenous osteomyelitis caused by
Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic
bone and joint infections due to susceptible organisms. Launch Date8.6745596E10 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10475141/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLINDAMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
0.92 ng/mL |
0.03 g 1 times / day steady-state, topical dose: 0.03 g route of administration: Topical experiment type: STEADY-STATE co-administered: |
CLINDAMYCIN plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10475141/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLINDAMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
13.54 ng × h/mL |
0.03 g 1 times / day steady-state, topical dose: 0.03 g route of administration: Topical experiment type: STEADY-STATE co-administered: |
CLINDAMYCIN plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10475141/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLINDAMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
5 g 7 times / day multiple, vaginal Recommended Dose: 5 g, 7 times / day Route: vaginal Route: multiple Dose: 5 g, 7 times / day Sources: Page: p.571 |
unhealthy, 16 - 51 n = 79 Health Status: unhealthy Condition: Bacterial Vaginosis Age Group: 16 - 51 Sex: F Population Size: 79 Sources: Page: p.571 |
Disc. AE: Vaginal pain or burning... AEs leading to discontinuation/dose reduction: Vaginal pain or burning (1.2%) Sources: Page: p.571 |
1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Sources: Anaphylactic shock Hypersensitivity reaction (severe) |
300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Sources: Anaphylactic shock Hypersensitivity reaction (severe) |
300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Sources: Anaphylactic shock Hypersensitivity reaction (severe) |
450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: Page: p.1 |
Disc. AE: Diarrhea, Clostridium difficile, Reaction skin... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Sources: Page: p.1Reaction skin (severe) Toxic epidermal necrolysis (grade 3-5) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Vaginal pain or burning | 1.2% Disc. AE |
5 g 7 times / day multiple, vaginal Recommended Dose: 5 g, 7 times / day Route: vaginal Route: multiple Dose: 5 g, 7 times / day Sources: Page: p.571 |
unhealthy, 16 - 51 n = 79 Health Status: unhealthy Condition: Bacterial Vaginosis Age Group: 16 - 51 Sex: F Population Size: 79 Sources: Page: p.571 |
Anaphylactic shock | Disc. AE | 1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Diarrhea, Clostridium difficile | Disc. AE | 1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Hypersensitivity reaction | severe Disc. AE |
1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Anaphylactic shock | Disc. AE | 300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Diarrhea, Clostridium difficile | Disc. AE | 300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Hypersensitivity reaction | severe Disc. AE |
300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Anaphylactic shock | Disc. AE | 300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Diarrhea, Clostridium difficile | Disc. AE | 300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Hypersensitivity reaction | severe Disc. AE |
300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Diarrhea, Clostridium difficile | Disc. AE | 450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: Page: p.1 |
Toxic epidermal necrolysis | grade 3-5 Disc. AE |
450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: Page: p.1 |
Reaction skin | severe Disc. AE |
450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: Page: p.1 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 1.0 |
moderate [Inhibition 100 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9 |
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | likely (co-administration study) Comment: inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin Page: 5.0 |
|||
minor | likely (co-administration study) Comment: inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin Page: 5.0 |
|||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined |
PubMed
Title | Date | PubMed |
---|---|---|
Efficacy of clindamycin vaginal ovule (3-day treatment) vs. clindamycin vaginal cream (7-day treatment) in bacterial vaginosis. | 2001 |
|
Superantigen antagonist peptides. | 2001 |
|
Streptococcal toxic shock syndrome revealed by a peritonitis. Case report and review of the literature. | 2001 |
|
Lemierre's syndrome with spondylitis and pulmonary and gluteal abscesses associated with Mycoplasma pneumoniae pneumonia. | 2001 Apr |
|
Chronic granulomatous disease: a case report. | 2001 Apr |
|
Thoracic spondylitis mimicking idiopathic scoliosis: a case report. | 2001 Apr |
|
Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. | 2001 Apr |
|
Activation of clindamycin phosphate by human skin. | 2001 Apr |
|
Severe babesiosis in Long Island: review of 34 cases and their complications. | 2001 Apr 15 |
|
Laparoscopic management of adnexal masses. | 2001 Apr-Jun |
|
Successful treatment regime for folliculitis decalvans despite uncertainty of all aetiological factors. | 2001 Feb |
|
Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. | 2001 Feb |
|
Dermatopharmacology of a new combination gel formulation for the topical treatment of acne. | 2001 Feb |
|
Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. | 2001 Feb |
|
Clostridium difficile--Associated diarrhea: A review. | 2001 Feb 26 |
|
[Guidelines for antibiotic prophylaxis of bacterial endocarditis in patients undergoing dental therapy]. | 2001 Jan |
|
Folliculitis decalvans. | 2001 Jan |
|
Clonal relationships among penicillin-susceptible, multiresistant serotype 6B Streptococcus pneumoniae isolates recovered in Greece and France. | 2001 Jan |
|
Emerging erythromycin resistance among group B streptococci in Korea. | 2001 Jan |
|
Antibiotic sensitivity of Propionibacterium acnes isolates from patients with acne vulgaris in a tertiary dermatological referral centre in Singapore. | 2001 Jan |
|
The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. | 2001 Jan-Feb |
|
Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. | 2001 Jul |
|
A rare case of primary group A streptococcal peritonitis. | 2001 Jul |
|
Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobic agents. | 2001 Jul |
|
Cutaneous botryomycosis of the cervicofacial region. | 2001 Jul |
|
Comparison of in-vitro activities of SCH27899 and other antibiotics against Mycoplasma pneumoniae. | 2001 Jun |
|
The emergence of erythromycin-resistant Streptococcus pyogenes in Seoul, Korea. | 2001 Jun |
|
Bilateral peritonsillar abscess: case report and presentation of its clinical appearance. | 2001 Jun |
|
Transfusion-transmitted babesiosis in Ontario: first reported case in Canada. | 2001 Jun 12 |
|
Infection of hamsters with epidemiologically important strains of Clostridium difficile. | 2001 Jun 15 |
|
Prevalence and phenotypes of erythromycin-resistant Streptococcus pneumoniae in Shanghai, China. | 2001 Mar |
|
Persistence of Plasmodium falciparum in the placenta after apparently effective quinidine/clindamycin therapy. | 2001 Mar |
|
[The therapeutic approach to necrotizing fasciitis]. | 2001 Mar |
|
[Cellulitis and necrotizing fasciitis: microbiology and pathogenesis]. | 2001 Mar |
|
Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America. | 2001 Mar |
|
In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics. | 2001 Mar |
|
Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae isolated from pigs with swine erysipelas in Japan, 1988-1998. | 2001 Mar |
|
Comparative in-vitro activity of trovafloxacin and other related drugs against isolates of streptococcus oralis. | 2001 Mar |
|
Antibiotic-resistant bacteria in pediatric chronic sinusitis. | 2001 Mar |
|
Detection and characterization of a bacteriocin, garviecin L1-5, produced by Lactococcus garvieae isolated from raw cow's milk. | 2001 Mar |
|
Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children. | 2001 Mar |
|
Tufted hair folliculitis after scalp injury. | 2001 Mar |
|
Treatment of nosocomial postoperative pneumonia in cancer patients: a prospective randomized study. | 2001 Mar |
|
Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. | 2001 Mar 30 |
|
[Dermo-hypodermitis and necrotizing fasciitis]. | 2001 Mar 31 |
|
The treatment of babesiosis. | 2001 Mar 8 |
|
Clinical inquiries. What are the most effective treatments for bacterial vaginosis in nonpregnant women? | 2001 May |
|
Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. | 2001 May 15 |
|
Prevalence of serotypes and molecular epidemiology of Streptococcus pneumoniae strains isolated from children in Beijing, China: identification of two novel multiply-resistant clones. | 2001 Spring |
|
In vitro activity of 19 antimicrobial agents against enterococci from healthy subjects and hospitalized patients and use of an ace gene probe from Enterococcus faecalis for species identification. | 2001 Spring |
Sample Use Guides
150 to 300 mg every 6 hours (Serious infections), 300 to 450 mg every 6 hours (More severe infections), 8 to 16 mg/kg/day divided into three or four equal doses (Serious infections in pediatric patients), 16 to 20 mg/kg/day divided into three or four equal doses (More severe infections in pediatric patients).
Route of Administration:
Oral
In Vitro Use Guide
Curator's Comment: The Minimum Inhibitory Concentration was 0.03-0.12 ug/ml (Streptococcus pneumoniae ATCC 49619) when testing aerobic pathogens and 0.06-0.25 ug/ml (Eubacterium lentum ATCC 43055) when testing anaerobs.
MIC=0.03-0.12 ug/ml (Aerobic Pathogens), MIC=0.06-0.25 ug/ml (Anaerobes).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:52:52 UTC 2023
by
admin
on
Sat Dec 16 15:52:52 UTC 2023
|
Record UNII |
3U02EL437C
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QD10AF01
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
CFR |
21 CFR 520.447
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
WHO-ATC |
J01FF01
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
WHO-VATC |
QJ01FF01
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
NDF-RT |
N0000175442
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
WHO-ATC |
G01AA10
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
CFR |
21 CFR 520.446
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
WHO-ATC |
D10AF51
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
LIVERTOX |
NBK548292
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
NDF-RT |
N0000175442
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
NDF-RT |
N0000175443
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
WHO-VATC |
QG01AA10
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
WHO-ATC |
D10AF01
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
FDA ORPHAN DRUG |
26988
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
NDF-RT |
N0000009982
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.2
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
NCI_THESAURUS |
C82922
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
FDA ORPHAN DRUG |
27088
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
||
|
WHO-VATC |
QD10AF51
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3745
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
Clindamycin
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
2550
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
CLINDAMYCIN
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
m3624
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | Merck Index | ||
|
3U02EL437C
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
DTXSID2022836
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
678
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
18323-44-9
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
C377
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
100000084276
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
SUB06665MIG
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
242-209-1
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
D002981
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
3U02EL437C
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
CHEMBL1753
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
446598
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
2582
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | RxNorm | ||
|
3037
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY | |||
|
DB01190
Created by
admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
18 STRAINS; MIC range listed
MIC90
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET ORGANISM->INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
PARENT -> METABOLITE |
IN VITRO
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
ROUTE OF ADMINSTRATION: IM |
|
||
MIC | BIOLOGICAL |
|
PATHOGEN: ANAEROBIC BACTERIA |
|
||
ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
|
|||
Biological Half-life | BIOLOGICAL |
|
POPULATION: ELDERLY |
|
||
Biological Half-life | PHARMACOKINETIC |
|
POPULATION: CHILDREN |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: RESISTANT |
|
||
MIC | BIOLOGICAL |
|
PATHOGEN: STAPHYLOCOCCUS spp. |
|
||
Tmax | PHARMACOKINETIC |
|
ROUTE OF ADMINISTRATION: ORAL |
|
||
MIC | BIOLOGICAL |
|
PATHOGEN: STAPHYLOCOCCUS spp. |
|
||
MIC | BIOLOGICAL |
|
PATHOGEN: STAPHYLOCOCCUS spp. |
|
||
Biological Half-life | PHARMACOKINETIC |
|
POPULATION: ADULTS |
|
||
Biological Half-life | PHARMACOKINETIC |
|
POPULATION: PREMATURE NEONATES |
|
||
MIC | BIOLOGICAL |
|
PATHOGEN: S. PNEUMONIAE AND OTHER STREPTOCOCCUS spp. |
|
||
Biological Half-life | PHARMACOKINETIC |
|
POPULATION: FULL-TERM NEONATES |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: SUSCEPTIBLE |
|
||
Biological Half-life | PHARMACOKINETIC |
|
POPULATION: INFANTS 1 MONTH TO 1 YEAR |
|
||
MIC | BIOLOGICAL |
|
PATHOGEN: S. PNEUMONIAE AND OTHER STREPTOCOCCUS spp. |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: SUSCEPTIBLE |
|
||